![](/img/cover-not-exists.png)
IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors
Molenaar, Remco J, Radivoyevitch, Tomas, Nagata, Yasunobu, Khurshed, Mohammed, Przychodzen, Bartlomiej, Makishima, Hideki, Xu, Mingjiang, Bleeker, Fonnet E, Wilmink, Johanna W, Carraway, Hetty, MukherLanguage:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-17-2796
Date:
January, 2018
File:
PDF, 2.83 MB
english, 2018